Skip to content
Clinical Trials for Alzheimer's Disease

Florida

Alzheimer's disease clinical trials in Florida

61 Alzheimer's disease studies are recruiting participants at sites in 50 cities across Florida as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 927-5895
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Florida by city

Cities with the most studies recruiting right now.

Every Florida city with a recruiting study

Miami (24), Tampa (20), Maitland (19), Orlando (19), Winter Park (11), Stuart (10), The Villages (10), Aventura (8), Daytona Beach (8), Wellington (8), Jacksonville (7), Lady Lake (7), Atlantis (6), Clermont (6), Miami Lakes (6), Port Orange (6), West Palm Beach (6), Boca Raton (5), Bonita Springs (5), Doral (5), Fort Myers (5), Hialeah (5), Naples (5), Ocala (5), Delray Beach (4), Homestead (4), Melbourne (4), Sarasota (4), Bradenton (3), Merritt Island (3), Miami Gardens (3), Brandon (2), New Port Richey (2), Virginia Gardens (2), Coconut Creek (1), Coral Springs (1), Cutler Bay (1), Deerfield Beach (1), Fort Lauderdale (1), Gainesville (1), Greenacres City (1), Miami Beach (1), Miami Springs (1), Mt. Dora (1), Ocoee (1), Ormond Beach (1), Pensacola (1), Tallahassee (1), Viera (1), Weston (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Florida

Basic details from each study's public record (the 12 most recently updated of 61). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

    • Phase 3
    • Ages 50 to 90
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Atlantis · Clermont · Lady Lake · and 10 more U.S. locations
    Registry record
    NCT07177352 · updated
  2. Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

    • Phase 2
    • Ages 50 to 90
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Stuart · Wellington · Winter Park
    Registry record
    NCT07781657 · updated
  3. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Recruiting in
    Bonita Springs · Clermont · Cutler Bay · and 13 more U.S. locations
    Registry record
    NCT05980949 · updated
  4. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Recruiting in
    Boca Raton · Deerfield Beach · Doral · and 7 more U.S. locations
    Registry record
    NCT06887192 · updated
  5. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Miami · Port Orange · Tampa · and 1 more U.S. location
    Registry record
    NCT06937229 · updated
  6. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Merritt Island · Orlando · Port Orange · and 1 more U.S. location
    Registry record
    NCT07011732 · updated
  7. A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Sanofi
    Recruiting in
    Naples · Orlando · Stuart · and 3 more U.S. locations
    Registry record
    NCT07688213 · updated
  8. A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

    • Phase 3
    • Ages 55 to 80
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Maitland · Ocala · Orlando · and 4 more U.S. locations
    Registry record
    NCT07717411 · updated
  9. ACP-204 in Adults With Alzheimer's Disease Psychosis

    • Phase 2/3
    • Ages 55 to 95
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Recruiting in
    Aventura · Daytona Beach · Doral · and 7 more U.S. locations
    Registry record
    NCT06159673 · updated
  10. A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

    • Phase 1
    • Ages 18 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Recruiting in
    Daytona Beach
    Registry record
    NCT07787169 · updated
  11. Flutemetamol F 18 Injection Formulation Comparison

    • Phase 2
    • Ages 50 to 110
    • All sexes
    Sponsor
    GE Healthcare
    Recruiting in
    Aventura · Miami · Winter Park
    Registry record
    NCT07873463 · updated
  12. A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Recruiting in
    Atlantis · Aventura · Delray Beach · and 8 more U.S. locations
    Registry record
    NCT07589595 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Florida on ClinicalTrials.gov.

Ask about studies in Florida

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5895

or send a short form

How should we reach you?

Call